Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial-Reference-Cited by-同舟云学术

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial

Published:2010-06-10 Issue:8 Volume:24 Page:1406-1411
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Dispenzieri A,Jacobus S,Vesole D H,Callandar N,Fonseca R,Greipp P R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2010129.pdf

Reference25 articles.

1. Rajkumar SV, Buadi F . Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007; 20: 665–680.

2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

3. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M . Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993–1999.

4. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82: 323–341.

5. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151–157.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone‐Targeted Bortezomib Inhibits Bortezomib‐Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone;Journal of Bone and Mineral Research;2022-01-22

2. Novel Perspectives in Pseudomyxoma Peritonei Treatment;Cancers;2021-11-27

3. Foot drop in patients treated with bortezomib – a case series and review of the literature;Leukemia & Lymphoma;2021-10-26

4. Bisphosphonates for delivering drugs to bone;British Journal of Pharmacology;2021-04-10

5. Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis;Hematology;2021-01-01